TEVA


2015-03-11 Options Report (C) (COP)

Posted on March 11th, by Mitchell Warren in Free Articles, Options Reports, Options Risk Management, Premium Articles, Unusual Options Activity. Comments Off on 2015-03-11 Options Report (C) (COP)

Options Report

(This Options Report is an example of what will be included in my ORM Equity/Option Trader Subscription Service for $9.99 per month)

Email me at Mitchell@OptionsRiskManagement.com or tweet me @MitchellKWarren on StockTwits/Twitter if you’d like for me to notify you when it is available or if you have any other questions.

Open Interest Updates From The Previous Trading Days Action

AECOM (ACM)- June $27.50 put open interest went from 3,632 to 8,398 contracts (more buying yesterday).
Air Products & Chemicals (APD)- Apr $140 put open interest went from 2,077 to 4,280 contracts (selling as part of a bull risk reversal yesterday).
Atmel (ATML)- Apr $9 call open interest went from 3,309 to 5,246 contracts (buying yesterday).
Bank of New York Mellon (BK)- Mar 20 $40 call open interest went from 17,027 to 18,663 contracts (more buying).
Anheuser Busch Inbev SA … Read More »


2015-03-05 Teva Pharmaceutical Option Trader Sees More Upside Later This Year (TEVA)

Posted on March 5th, by Mitchell Warren in Free Articles, Options Risk Management, Trade Ideas, Unusual Options Activity. Comments Off on 2015-03-05 Teva Pharmaceutical Option Trader Sees More Upside Later This Year (TEVA)

Teva Pharmaceutical Option Trader Sees More Upside Later This Year (TEVA)

Notes: Today, someone sold their 4,000 (TEVA) Mar 20 $52.50 calls for $4.05 each (21% gain from their $3.35 entry) and moved into 6,000 Jan 2016 $45/$60 bull risk reversals for a $2.90 debit (bought the $60 calls and sold the $45 puts). Option activity was nearly 3x the average daily volume (typically trades 8,662 contracts total). Prior to this trade, Teva Pharmaceuticals announced that they were selling ANDA (Flecainide Acetate tablets USP 50mg, 100mg and 150mg) to ANI Pharmaceuticals and that they will be presenting at the Barclays Global Healthcare Conference on March 12th. Also, on March 2nd, Teva agreed to sell their Sellersville, PA facility to G&W Laboratories as part of a cost cutting effort. The $54B generic drug maker trades at a … Read More »


2014-01-10 Smart Money Report (KMX) (PWRD)

Posted on January 10th, by Mitchell Warren in Free Articles, Options Risk Management, Smart Money Report, Unusual Options Activity. Comments Off on 2014-01-10 Smart Money Report (KMX) (PWRD)

Smart Money Report

HPQ- A likely rollout from 7,500 Feb. $27 puts (credit) into 7,500 Feb. $25 puts (debit). Volume was above the open interest in the Feb. $25 puts.
KMX- The Feb. $45/$47 1×2 call spread was put on 5k times for a $0.25 debit. Volume was above the open interest in both options.
PWRD- A rollout from 1,400 Jan. $17 calls (credit) into 2,300 Mar. $20 calls (debit). Volume was above the open interest in the Mar. $20 calls.
TEVA- 5,100 Mar. $45 calls were purchased for $0.64 each, against open interest of 2,704 contracts. Earnings are due out on 2/6.
VIX- The spot Volatility Index is down 3.80% today and is on pace for the lowest close of 2014, despite the weaker than expected December Non-Farm Payrolls. The call to put ratio in (VIX) options is 4.41, led by a buyer of near … Read More »


2014-01-10 Unusual Options Activity (HPQ) (TEVA)

Posted on January 10th, by Mitchell Warren in Options Risk Management, Unusual Options Activity. Comments Off on 2014-01-10 Unusual Options Activity (HPQ) (TEVA)

Unusual Options Activity

In today’s Unusual Options Activity Report we highlight a put rollout in Hewlett-Packard (HPQ) and large call buying in Teva Pharmaceutical (TEVA).

You need to be logged in to see this part of the content. Please Login to access.



Wordpress SEO Plugin by SEOPressor